GTBP
Price
$3.80
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
11.14M
PTCT
Price
$49.84
Change
+$0.29 (+0.59%)
Updated
Jun 27 closing price
Capitalization
3.95B
31 days until earnings call
Interact to see
Advertisement

GTBP vs PTCT

Header iconGTBP vs PTCT Comparison
Open Charts GTBP vs PTCTBanner chart's image
GT Biopharma
Price$3.80
Change-$0.00 (-0.00%)
Volume$430
Capitalization11.14M
PTC Therapeutics
Price$49.84
Change+$0.29 (+0.59%)
Volume$1.39M
Capitalization3.95B
GTBP vs PTCT Comparison Chart in %
Loading...
GTBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PTCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GTBP vs. PTCT commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GTBP is a Buy and PTCT is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (GTBP: $3.80 vs. PTCT: $49.84)
Brand notoriety: GTBP and PTCT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GTBP: 1% vs. PTCT: 108%
Market capitalization -- GTBP: $11.14M vs. PTCT: $3.95B
GTBP [@Biotechnology] is valued at $11.14M. PTCT’s [@Biotechnology] market capitalization is $3.95B. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GTBP’s FA Score shows that 0 FA rating(s) are green whilePTCT’s FA Score has 1 green FA rating(s).

  • GTBP’s FA Score: 0 green, 5 red.
  • PTCT’s FA Score: 1 green, 4 red.
According to our system of comparison, both GTBP and PTCT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GTBP’s TA Score shows that 5 TA indicator(s) are bullish while PTCT’s TA Score has 6 bullish TA indicator(s).

  • GTBP’s TA Score: 5 bullish, 4 bearish.
  • PTCT’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, PTCT is a better buy in the short-term than GTBP.

Price Growth

GTBP (@Biotechnology) experienced а +24.59% price change this week, while PTCT (@Biotechnology) price change was -0.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

PTCT is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTCT($3.95B) has a higher market cap than GTBP($11.1M). GTBP YTD gains are higher at: 24.590 vs. PTCT (10.412). PTCT has higher annual earnings (EBITDA): 839M vs. GTBP (-12M). PTCT has more cash in the bank: 2.03B vs. GTBP (2.37M). GTBP has less debt than PTCT: GTBP (0) vs PTCT (390M). PTCT has higher revenues than GTBP: PTCT (1.77B) vs GTBP (0).
GTBPPTCTGTBP / PTCT
Capitalization11.1M3.95B0%
EBITDA-12M839M-1%
Gain YTD24.59010.412236%
P/E RatioN/A7.66-
Revenue01.77B-
Total Cash2.37M2.03B0%
Total Debt0390M-
FUNDAMENTALS RATINGS
GTBP vs PTCT: Fundamental Ratings
GTBP
PTCT
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
99
Overvalued
PROFIT vs RISK RATING
1..100
10098
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3748
P/E GROWTH RATING
1..100
10018
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GTBP's Valuation (34) in the null industry is somewhat better than the same rating for PTCT (99) in the Biotechnology industry. This means that GTBP’s stock grew somewhat faster than PTCT’s over the last 12 months.

PTCT's Profit vs Risk Rating (98) in the Biotechnology industry is in the same range as GTBP (100) in the null industry. This means that PTCT’s stock grew similarly to GTBP’s over the last 12 months.

PTCT's SMR Rating (100) in the Biotechnology industry is in the same range as GTBP (100) in the null industry. This means that PTCT’s stock grew similarly to GTBP’s over the last 12 months.

GTBP's Price Growth Rating (37) in the null industry is in the same range as PTCT (48) in the Biotechnology industry. This means that GTBP’s stock grew similarly to PTCT’s over the last 12 months.

PTCT's P/E Growth Rating (18) in the Biotechnology industry is significantly better than the same rating for GTBP (100) in the null industry. This means that PTCT’s stock grew significantly faster than GTBP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GTBPPTCT
RSI
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 4 days ago
80%
Momentum
ODDS (%)
Bullish Trend 4 days ago
85%
Bearish Trend 4 days ago
89%
MACD
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
77%
Advances
ODDS (%)
Bullish Trend 5 days ago
85%
Bullish Trend 4 days ago
74%
Declines
ODDS (%)
Bearish Trend 14 days ago
90%
Bearish Trend 11 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
82%
Aroon
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
GTBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PTCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RTDSX16.020.08
+0.50%
Russell Inv Multifactor US Equity S
GSPQX17.500.08
+0.44%
Goldman Sachs US Eq Div and Premium C
VGSNX19.420.06
+0.31%
Vanguard Real Estate Index Institutional
DBMAX28.560.05
+0.18%
BNY Mellon Sm/Md Cp Gr A
STCEX4.61-0.01
-0.22%
Virtus Ceredex Small-Cap Value Eq C

GTBP and

Correlation & Price change

A.I.dvisor indicates that over the last year, GTBP has been loosely correlated with BDRX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if GTBP jumps, then BDRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GTBP
1D Price
Change %
GTBP100%
N/A
BDRX - GTBP
39%
Loosely correlated
-6.21%
SLGL - GTBP
34%
Loosely correlated
-0.81%
RAPT - GTBP
33%
Loosely correlated
-13.36%
TRAW - GTBP
31%
Poorly correlated
N/A
PTCT - GTBP
28%
Poorly correlated
+0.59%
More

PTCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTCT has been loosely correlated with RXRX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if PTCT jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTCT
1D Price
Change %
PTCT100%
+0.59%
RXRX - PTCT
44%
Loosely correlated
-6.85%
SYRE - PTCT
44%
Loosely correlated
-4.99%
XNCR - PTCT
42%
Loosely correlated
-3.10%
BEAM - PTCT
42%
Loosely correlated
-1.98%
IDYA - PTCT
42%
Loosely correlated
-4.13%
More